Breast and Cervical Cancer Early Detection and Control Advisory Committee, 71538 [05-23425]
Download as PDF
<![CDATA[
71538
Federal Register / Vol. 70, No. 228 / Tuesday, November 29, 2005 / Notices
Dated: November 18, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E5–6671 Filed 11–28–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control.
[FR Doc. 05–23425 Filed 11–28–05; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
Breast and Cervical Cancer Early
Detection and Control Advisory
Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting:
Name: Breast and Cervical Cancer
Early Detection and Control Advisory
Committee (BCCEDCAC).
Times and Dates: 8:30 a.m.–5 p.m.,
December 6, 2005. 8:30 a.m.–1 p.m.,
December 7, 2005.
Place: Embassy Suites Hotel,
Centennial Olympic Park, 267 Marietta
Street, Atlanta, Georgia 30313.
Phone: 1–404–223–2300.
Status: Open to the public, limited
only by the space available.
Purpose: The committee is charged
with advising the Secretary, Department
of Health and Human Services, and the
Director, CDC, regarding the early
detection and control of breast and
cervical cancer. The committee makes
recommendations regarding national
program goals and objectives;
implementation strategies; and program
priorities including surveillance,
epidemiologic investigations, education
and training, information dissemination,
professional interactions and
collaborations, and policy.
Matters to be Discussed: The agenda
will include discussion and review of
the vision for National Cancer
Prevention and Control Program;
strategies for Performance-Based
Funding; Case Management; update of
expert panel meetings; HPV Testing and
the Breast and Cervical Program; and
HPV Vaccine update.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Debra Younginer, Executive Secretary,
BCCEDCAC, Division of Cancer
Prevention and Control, National Center
for Chronic Disease Prevention and
Health Promotion, CDC, 4770 Buford
Highway, Mailstop K–57, Chamblee,
Georgia 30316, Telephone: 770–488–
1074.
VerDate Aug<31>2005
20:13 Nov 28, 2005
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0374]
Nonprescription Drugs Advisory
Committee and Pulmonary-Allergy
Drugs Advisory Committee; Notice of
Meeting and Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committees:
Nonprescription Drugs Advisory
Committee and the Pulmonary-Allergy
Drugs Advisory Committee.
General Function of the Committees:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on January 24, 2006, from 8 a.m.
to 5 p.m. Interested persons and
organizations may submit written or
electronic comments until January 6,
2006, to the Division of Dockets
Management (see Addresses).
Addresses: Electronic comments
should be submitted to https://
www.fda.gov/dockets/ecomments.
Select ‘‘2005N–0374 Use of OzoneDepleting Substance: Essential-Use
Determination of Over-the-Counter
(OTC) Epinephrine Metered Dose
Inhalers’’ and follow the prompts to
submit your statement. Written
comments should be submitted to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
Location: Holiday Inn Select
Bethesda, The Ballrooms, 8120
Wisconsin Ave., Bethesda, MD. The
hotel telephone number is 301–652–
2000.
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
Contact Person: Darrell Lyons, Center
for Drug Evaluation and Research (HFD
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093) Rockville,
MD 20857, (301–827–7001, FAX: 301–
827–6776, e-mail: lyonsd@cder.fda.gov,
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area) codes 3014512541 or 3014512545.
Please call the Information Line for up
to date information on this meeting.
Agenda: The committee will discuss
the continued need for the designation
of OTC epinephrine-metered dose
inhalers for the treatment of asthma as
an essential use of ozone-depleting
substances (ODSs) under § 2.125 (21
CFR 2.125). ODSs are substances that
deplete the stratospheric ozone, which
include chlorofluorocarbons (CFCs).
Once released, CFCs rise to the
stratosphere. In the stratosphere, CFCs
are gradually broken down by strong
ultraviolet light, and they release
chlorine atoms that then deplete
stratospheric ozone. Depletion of
stratospheric ozone by CFCs and other
ODSs leads to higher ultraviolet B
radiation levels, which in turn increase
skin cancers and cataracts, as well as
cause other significant environmental
damage.
FDA is soliciting comments and data
to support or refute an essential-use
designation for OTC epinephrine
metered-dose inhaler (MDI) drug
products. These products include the
only OTC drug available in an MDI
dosage form for the treatment of asthma.
The OTC epinephrine MDIs use CFCs as
propellants. The OTC indication is ‘‘for
temporary relief of shortness of breath,
tightness of chest, and wheezing due to
bronchial asthma.’’ In some instances,
use of this product early during an
asthma attack could avert a serious or
life-threatening worsening of the attack.
There are currently a limited number of
marketed OTC drug products containing
epinephrine in a MDI dosage form.
According to § 2.125(f)(1), the
following are criteria for continued ODS
essential-use designation:
(1) Substantial technical barriers exist
to formulating the product without
ODSs;
(2) The product will provide an
otherwise unavailable important public
health benefit; and
(3) Use of the product does not release
cumulative significant amounts of ODSs
into the atmosphere or the release is
warranted in view of the high
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 70, Number 228 (Tuesday, November 29, 2005)]
[Notices]
[Page 71538]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-23425]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Breast and Cervical Cancer Early Detection and Control Advisory
Committee
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting:
Name: Breast and Cervical Cancer Early Detection and Control
Advisory Committee (BCCEDCAC).
Times and Dates: 8:30 a.m.-5 p.m., December 6, 2005. 8:30 a.m.-1
p.m., December 7, 2005.
Place: Embassy Suites Hotel, Centennial Olympic Park, 267 Marietta
Street, Atlanta, Georgia 30313.
Phone: 1-404-223-2300.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Secretary,
Department of Health and Human Services, and the Director, CDC,
regarding the early detection and control of breast and cervical
cancer. The committee makes recommendations regarding national program
goals and objectives; implementation strategies; and program priorities
including surveillance, epidemiologic investigations, education and
training, information dissemination, professional interactions and
collaborations, and policy.
Matters to be Discussed: The agenda will include discussion and
review of the vision for National Cancer Prevention and Control
Program; strategies for Performance-Based Funding; Case Management;
update of expert panel meetings; HPV Testing and the Breast and
Cervical Program; and HPV Vaccine update.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Debra Younginer, Executive
Secretary, BCCEDCAC, Division of Cancer Prevention and Control,
National Center for Chronic Disease Prevention and Health Promotion,
CDC, 4770 Buford Highway, Mailstop K-57, Chamblee, Georgia 30316,
Telephone: 770-488-1074.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both CDC and the Agency for Toxic Substances and Disease Registry.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control.
[FR Doc. 05-23425 Filed 11-28-05; 8:45 am]
BILLING CODE 4163-18-P
